South Korea · Delayed Price · Currency is KRW curacle co.,ltd. Company Description
Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels.
Its products cover age-related vascular diseases, intractable metabolic diseases, and cancer targeting/immunotherapy.
The company’s products in pipeline include CU06, which covers treatment and medical indications, such as diabetic macular edema/retinopathy, acute respiratory distress syndrome, myocardial infarction, stroke treatment, concomitantly used with immunotherapy, inflammatory bowel disease treatment, and hereditary angioedema; CU03, which is in Phase 2a clinical trial study for the treatment of age-related macular degeneration; and CU01, a diabetic nephropathy medicine that completed Phase 2a clinical trial.
Its products in back-up pipeline include CU02, a product for nonalcoholic steatohepatitis treatment; CU04, a product for the treatment of cancer (c-Myc inhibitor); and CU05, a product for the treatment of cancer (Amigo2-PDK1 inhibitor).
The company was founded in 2016 and is based in Seoul, South Korea.
| Country | South Korea |
| Founded | 2016 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Jaehyeon Yoo |
Contact Details
Address: 23-1, Hyoryeong-ro Seoul, 06694 South Korea | |
| Phone | 82 3 1706 8300 |
| Website | curacle.com |
Stock Details
| Ticker Symbol | 365270 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jaehyeon Yoo | Chief Executive Officer |